Unfolding narratives, shaping futures

We're always working to initiate change for patients

This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.

UroGen® profile

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

See our pipeline

Our leadership

See full leadership team

News releases

Apr 27, 2025

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

Data Presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 27, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty

Read story

Apr 27, 2025

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 27, 2025-- UroGen Pharma Ltd.

Read story

Apr 27, 2025

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

Data Presented at the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 27, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty

Read story

Events

Mar 10, 2025

UroGen Pharma Q4 2024 Earnings Call

Listen to webcast

Mar 3, 2025

TD Cowen 45th Annual Health Care Conference

Listen to webcast

Feb 20, 2025

Advancing Our Mission to Transform Cancer Care

Listen to webcast

Feb 11, 2025

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Listen to webcast

Feb 5, 2025

Guggenheim Securities SMID Cap Biotech Conference

Listen to webcast

Nov 6, 2024

UroGen Pharma Q3 2024 Earnings Call

Listen to webcast

Sep 17, 2024

2024 Cantor Global Healthcare Conference

Listen to webcast

Sep 9, 2024

H.C. Wainwright 26th Annual Global Investment Conference

Listen to webcast

Aug 13, 2024

UroGen Pharma Q2 2024 Earnings Call

Listen to webcast

Jun 13, 2024

UGN-102 12-Month Durability of Response Data Event

Listen to webcast
Connect with us
For more information about our products